Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

NCT03262584 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-06-17

No results posted yet for this study

Summary

The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens, is more accurate than other noninvasive options and can report fungal genomic load.

Conditions

  • Invasive Fungal Disease
  • Fever and Neutropenia
  • Invasive Fungal Infections
  • Immunocompromised

Sponsors & Collaborators

  • Ann & Robert H Lurie Children's Hospital of Chicago

    collaborator OTHER
  • Karius, Inc.

    lead INDUSTRY

Principal Investigators

  • Amy Armstrong, MD · Ann & Robert H Lurie Children's Hospital of Chicago

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2018-07-31
Completion
2018-09-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03262584 on ClinicalTrials.gov